JNTX-101, a novel albumin-encapsulated gemcitabine prodrug, is efficacious and operates via caveolin-1-mediated endocytosis

JNTX-101, a novel albumin-encapsulated gemcitabine prodrug, is efficacious and operates via caveolin-1-mediated endocytosis

Albumin is an attractive candidate carrier for the development of novel therapeutic drugs. Gemcitabine has been FDA approved for the treatment of solid tumors; however, new drugs that optimize gemcitabine delivery are not available for clinical use. The aim of this study was to test the efficacy of...

Full description

Bibliographic Details
Main Authors: Tiantian Cui, Sergio Corrales-Guerrero, Veronica Castro-Aceituno, Sindhu Nair, Daniel C. Maneval, Curtis Monnig, Patrick Kearney, Sam Ellis, Nicholas Raheja, Neil Raheja, Terence M. Williams
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:Molecular Therapy: Oncolytics
Subjects:
JNTX-101
albumin
gemcitabine
caveolin-1
Cav-1
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770523000633

Internet

http://www.sciencedirect.com/science/article/pii/S2372770523000633

Similar Items